CBF-AML is characterized by the presence of aberrancies at CBF genes, and comprises t(8;21) and inv (16)/t(16;16), resulting in the RUNX1-RUNX1T1 and CBFB-MYH11 gene fusions, respectively. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.